Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05468671
Other study ID # IRB-2020-406
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date January 4, 2021
Est. completion date September 8, 2022

Study information

Verified date October 2022
Source Zhejiang Cancer Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a prospective, randomized, controlled trial. In this study, 30 patients who underwent endotracheal tumor resection under rigid bronchoscope or stent placement for acquired tracheoesophageal fistula were selected as the subjects. The patients were randomly divided into remazolam general anesthesia group (R group) and propofol general anesthesia control group (P group). Remazolam general anesthesia group (R group): Remazolam 0.4 mg/kg, oxycodone 0.2 mg/kg and rocuronium 0.9 mg/kg were given for anesthesia induction. Propofol general anesthesia control group (P group): Propofol 1.5mg/kg, oxycodone 0.2mg/kg and rocuronium 0.9mg/kg were given for induction of anesthesia. After induction, high-frequency jet ventilation was used in both groups, the respiratory rate was 30-60 times/min, the inspiratory-to-breath ratio was 1:2, and the driving pressure was 0.8-1.0 KPa. Group R was given remazolam 1mg/kg/h and remifentanil 6-8ug/kg/h for maintenance. Group P was given propofol 4-8 mg/kg/h and remifentanil 6-8ug/kg/h for anesthesia maintenance. The dosage of propofol or remazolam was adjusted according to BIS and intraoperative hemodynamic changes. Rocuronium bromide 10 mg was added every half hour. Intraoperative application of vasoactive drugs to maintain mean arterial pressure above 60mmHg to avoid perioperative hypotension. Blood oxygen saturation and end-tidal carbon dioxide were monitored to avoid perioperative hypoxemia and hypercapnia, and warm measures were used to maintain the patient's intraoperative body temperature above 36.0°C. After surgery, group R was treated with sugammadex sodium 2-4 mg/kg to antagonize rocuronium bromide, and 0.5 mg of flumazenil was used to antagonize remazolam by intravenous injection; group P was treated with sugammadex 2-4 mg/kg to antagonize rocuronium.


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date September 8, 2022
Est. primary completion date August 4, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients undergoing bronchoscopy endotracheal tumor resection or stenting of acquired tracheoesophageal fistula within a limited time - >18 Years - ASA ?-? Exclusion Criteria: - <18Years - Refuse to participate - A history of schizophrenia, epilepsy, Parkinson's disease or myasthenia gravis; - Severe hepatic dysfunction (Child-Pugh class C) - Severe renal dysfunction (requiring dialysis) - Patients with ASA grade ? and above - Emergency Surgery

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Remimazolam
Remimazolam is a new drug innovation in anesthesia. It combines the properties of two unique drugs already established in anesthesia - Midazolam and remifentanil. It acts on GABA receptors like midazolam and has organ-independent metabolism like remifentanil.
Propofol
Propofol is used to put you to sleep and keep you asleep during general anesthesia for surgery or other medical procedures.
Rocuronium
Rocuronium is a non-depolarizing neuromuscular blocker
Remifentanil
Remifentanil is an esterase-metabolized opioid
oxycodone
Oxycodone is an opiate painkiller.
Sugammadex Sodium
Sugammadex sodium is an organic sodium salt that is the octasodium salt of sugammadex. Used for reversal of neuromuscular blockade induced by rocuronium and vecuronium in adults undergoing surgery
Flumazenil
Flumazenil is used to reverse the effects of a benzodiazepine

Locations

Country Name City State
China Zhejiang Cancer Hospital Hanzhou

Sponsors (1)

Lead Sponsor Collaborator
Zhejiang Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recovery time in seconds Taking the stop of general anesthesia as the starting point for timing, the time for the patient to correctly complete the three commands of nodding, mouth opening and tongue extension is recorded, with seconds as the timing unit postoperative, 2 hours
Secondary Modified Brice Questionnaire in YES or NO Modified Brice interview over quality assurance techniques in detecting intraoperative awareness. postoperative,24 hours
Secondary Intraoperative mean arterial blood pressure in mmHg Fluctuations in intraoperative systolic, diastolic pressures and mean arterial pressure will be recorded Intraoperative,4hours
Secondary Perioperative Nutrition Status Assessment Scale (PONS) in YES or NO PONS is a modified version of the malnutrition universal screening tool and determines the presence of nutrition risk based on BMI, recent body weight loss, decrement of dietary intake, and preoperative albumin concentration. Baseline, 1 year
Secondary Onset time in seconds The time from the start of peripheral intravenous injection of general anesthetic to the patient's loss of consciousness. Time is measured in seconds. Induction of anesthesia,10 minutes
Secondary The incidence of Postoperative delirium in rate The proportion of cases of postoperative delirium in the enrolled patients postoperative,24 hours
Secondary Intraoperative heart rate in beats per minute Fluctuations in intraoperative heart rate will be recorded Intraoperative,4hours
Secondary The incidence of postoperative vomiting in rate The proportion of cases of postoperative vomiting in the enrolled patients postoperative,24 hours
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03210077 - Romanian Entropy Clinical Study Network
Completed NCT04851574 - PKPD of Rocuronium and Sugammadex Profile in Pediatric Patients
Recruiting NCT03705728 - Automated Administration of Intravenous Compared With Inhalatory Anesthesia on the Occurrence of Postoperative Delirium N/A
Recruiting NCT06180876 - Effect of Remimazolam on Postoperative Delirium N/A
Recruiting NCT02213718 - The Effect of Desflurane on Myocardial Function in Patients Undergoing Coronary Artery Bypass Grafting Phase 4
Recruiting NCT06216002 - Incidence of Residual Neuromuscular Blockade in Fraility in OncoGynae Surgery N/A
Recruiting NCT05208502 - Observational of Emergence Time Between Patients Receive General Anesthesia With BIS or Spectrogram EEG Monitor
Completed NCT02617680 - Factors Affecting the Effective End-tidal Concentration of Desflurane Anaesthesia N/A
Recruiting NCT05935930 - Postoperative Effects of Propofol Versus Sevoflurane Anesthesia Phase 4